ISRG Trades at a Premium P/E: Buy, Sell or Hold the Stock Now?

Intuitive Surgical ISRG currently trades at a forward 12-month P/E ratio of 33.02X, above the Medical - Instruments industry's 26.53X, underscoring a valuation premium that investors must weigh against the company's growth prospects. The stock carries a Value Score of D, suggesting that shares are not particularly inexpensive despite the compression in its valuation multiple.

Second-quarter 2026 results nevertheless provided a solid operating baseline. Revenues increased 19% year over year to $2.89 billion, while adjusted earnings per share (EPS) rose 28% to $2.80. Total procedures increased 16%, including 15% growth in da Vinci procedures and 36% growth in Ion procedures. Recurring revenues also climbed 19% to $2.47 billion, representing 85% of total revenues. Utilization remained healthy, with da Vinci system utilization increasing 3% and Ion utilization rising 11%.

The second-quarter performance remained strong, although revenue growth moderated from 23% in the first quarter. U.S. da Vinci procedure growth slowed to 12% from 14% in the first quarter, reflecting some moderation in deferrable procedures. However, the company continued to deliver strong international growth and higher utilization from its expanding da Vinci 5 installed base.

With the premium multiple sitting well above the broader industry, the real test for investors is whether management's forward guidance justifies paying up today.

ISRG’s Premium Valuation Raises Concern

Image Source: Zacks Investment Research

Forward Guidance Signals Sustained Growth Potential

Management's updated outlook remains constructive for investors weighing the premium multiple. Intuitive Surgical maintained its 2026 da Vinci procedure-growth forecast at 13.5-15.5%, with growth expected to be closer to the midpoint. General surgery in the United States and procedures outside urology internationally are expected to remain the primary drivers. The outlook incorporates risks from U.S. patient behavior, obesity drugs, China tender volumes and competition, European capital pressures and Japan's recovery.

Importantly, the company raised its 2026 adjusted gross-margin outlook to 68-69% from 67.5-68.5%. This suggests that product cost reductions and operating leverage are increasingly offsetting higher freight and semiconductor-memory costs, as well as the favorable margin impact of faster growth in newer platforms. Operating expenses are now expected to grow 11-13%, with R&D continuing to expand faster than SG&A as Intuitive Surgical prioritizes innovation.

The guidance therefore points to sustained growth rather than a material deterioration in fundamentals, although the slower U.S. procedure trajectory remains a factor investors should monitor.

The Zacks Consensus Estimate for 2026 earnings is pegged at $10.74 per share, implying solid 20.3% year-over-year growth. Intuitive Surgical currently carries a Zacks Rank #3 (Hold), reflecting a neutral stance. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Intuitive Surgical, Inc. Price and Consensus

Intuitive Surgical, Inc. price-consensus-chart | Intuitive Surgical, Inc. Quote

Recent Product and Pipeline Developments

Intuitive Surgical's product ecosystem continues to provide multiple avenues for future growth. The company placed 468 da Vinci systems in the second quarter, up 18% year over year, with 246 being da Vinci 5 systems. Its da Vinci 5 installed base exceeded 1,700 systems and has been used by more than 15,000 surgeons. Meanwhile, SP procedures surged 61%, supported by expanded indications, new instruments and broader geographic adoption.

Ion remains an important growth platform, with procedures rising 36% to 48,000. The company is advancing its ROSE and EBUS programs, while a next-generation flexible robotic endoscope for gastrointestinal applications has been submitted for FDA 510(k) clearance.

Intuitive Surgical is investing in AI and digital capabilities using surgical video, robotic data and connected medical records. The company believes these capabilities will support decision-making, augmented dexterity, and aspects of future automation. Cardiac procedures and nipple-sparing mastectomy are also showing early momentum, growing 39% and 43%, respectively, in the second quarter.

Share-Price Movement and Competitive Landscape

ISRG shares have declined 23.7% over the past six months, compared with the Zacks Medical – Instruments industry's 0.7% drop, while the broader Medical sector has gained 0.9% during the same period, leaving Intuitive Surgical lagging both its industry and the wider medical sector.

Intuitive Surgical remains the clear incumbent in soft-tissue surgical robotics, with nearly 13,000 da Vinci and Ion systems installed globally by the end of second quarter of 2026, with total procedures rising 16% year over year. This includes 15% growth in da Vinci and 36% in Ion procedures. Medtronic's MDT Hugo is gaining ground but remains earlier in its commercialization cycle.

Medtronic’s Hugo platform is now available in more than 35 countries and has been used in tens of thousands of procedures, while its U.S. rollout began with the first commercial procedure in February 2026. Medtronic is also seeking to expand Hugo beyond urology into general and gynecologic surgery, potentially broadening its competitive reach.

Johnson & Johnson's JNJ OTTAVA represents a newer competitive threat following its July 2026 FDA De Novo authorization for multiple upper-abdominal general-surgery procedures. Johnson & Johnson’s table-integrated architecture is designed to reduce OR footprint and improve workflow, but its commercial presence is still at an early stage.

Johnson & Johnson is planning an initial U.S. launch with select customers. ISRG is unlikely to lose its U.S. market leadership anytime soon, with Medtronic and Johnson & Johnson still in a very early stage of commercialization of their robotic platform in the region.

ISRG’s 6-Month Price Performance

Image Source: Zacks Investment Research

Bottom Line

ISRG's premium valuation and D Value Score leave limited room for disappointment, particularly as U.S. procedure growth moderates and newer platforms require continued investment. Nevertheless, the company's strong second-quarter results, sustained outlook for procedure growth, improved margin guidance and expanding robotic ecosystem support a constructive view for the rest of 2026.

Although ISRG is trading at a premium valuation, it has significantly fallen from its high in early 2025, making the stock seemingly cheaper. Existing investors may therefore prefer holding ISRG stock rather than exiting solely because of its premium valuation. While the stock is not a clear bargain yet, continued da Vinci 5 adoption, strong SP and Ion growth, international expansion and the emerging AI-enabled pipeline provide meaningful support for future earnings.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research